Randomized Controlled Trial
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2025; 16(7): 106821
Published online Jul 15, 2025. doi: 10.4239/wjd.v16.i7.106821
Lactobacillus rhamnosus LRa05 on glycemic control and gut microbiota in patients with type 2 diabetes
Lin Geng, Ting-Ting Sun, Wen-Bo Xia, Yin Qin, Di Huo, Guang-Jing Qu
Lin Geng, Ting-Ting Sun, Wen-Bo Xia, Yin Qin, Di Huo, Guang-Jing Qu, Department of Second Inpatient, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China
Lin Geng, Ting-Ting Sun, Wen-Bo Xia, Yin Qin, Di Huo, Guang-Jing Qu, National Clinical Research Center for Geriatric Diseases, PLA General Hospital, Beijing 100853, China
Author contributions: Lin G contributed to conceptualization, methodology, software, and writing the original draft; Sun TT contributed to data curation, formal analysis, and investigation; Xia WB contributed to formal analysis, investigation, and methodology; Qin Y contributed to supervision and formal analysis; Huo D contributed to software and validation; Qu GJ contributed to conceptualization, project administration, and reviewing and editing; All authors read and approved the final manuscript.
Institutional review board statement: Our study received approval from the Ethics Committee of the First Affiliated Hospital of Harbin Medical University approved this study (IRB-AF/SC-04-02).
Clinical trial registration statement: The trial was registered at Chinese Clinical Trial Registry (https: //www.chictr.org.cn/bin/home) , number ChiCTR2300073308.
Informed consent statement: Informed consent was obtained from all individual participants included in the study.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Data sharing statement: All data generated and analyzed during this study are included in the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guang-Jing Qu, Department of Second Inpatient, The First Affiliated Hospital of Harbin Medical University, No. 23 Post Street, Nangang District, Harbin 150001, Heilongjiang Province, China. quguangjing2022@126.com
Received: March 10, 2025
Revised: March 26, 2025
Accepted: May 22, 2025
Published online: July 15, 2025
Processing time: 129 Days and 20.2 Hours
Core Tip

Core Tip: Lactobacillus rhamnosus LRa05 is a probiotic that has shown potential in managing type 2 diabetes by improving glycemic control and gut microbiota composition. In a study involving 76 participants over 12 weeks, those who consumed LRa05 experienced significant reductions in fasting blood glucose levels and improved lipid profiles, particularly an increase in high-density lipoprotein cholesterol. The probiotic also positively influenced gut health by promoting beneficial bacteria such as Bifidobacterium while reducing potentially harmful Bacillota levels. Although there were no notable changes in insulin sensitivity or inflammation markers, the overall findings suggest that LRa05 plays a crucial role in diabetes management.